Prognostic Value of MMP-9 in Ovarian Cancer: A Meta-analysis

Abstract

Objective: Matrix metalloproteinase-9(MMP-9) plays an important role in tumor cell invasion. Although it has been studied frequently in ovarian cancer, its prognostic impact is still equivocal. The aim of this study was to more precisely estimate its prognostic significance. Method:We searched Pubmed, Embase, OVID, Sciencedirect and CBM databases to identify eligible studies. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs) were pooled across studies using fixed-effects or random-effects models. We also performed subgroup analysis. Results: 30 studies (n=2552 patients) focusing on prognosis or expression of MM-9 were included. Increased expression of MMP-9 was associated with poor prognosis in ovarian cancer patients (HR=1.68, 95%CI 1.09-2.59, p=0.02). Besides, MMP-9 expression in ovarian cancer was significantly higher than non-malignant tumors (OR=11.46, 95%CI 8.47-15.50, P<0.00001). Moreover, increased expression of MMP-9 was significantly associated with FIGO stage (OR=4.85, 95%CI 2.60-9.04, P<0.00001), grade of differentiation (OR=3.34, 95%CI 2.46-4.54, P<0.00001), lymph node metastasis (OR=5.75, 95%CI 3.71-8.92, P<0.00001) and there was no association with histological type of ovarian cancer. Conclusions: Increased expression of MMP-9 was associated with poor prognosis in ovarian cancer patients. Down-regulation of MMP-9 is an attractive therapeutic approach which might improve outcome of ovarian cancer.

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy

“…CD44 , PTPRC ), and gene involved in MER-TK signaling pathway; the only downregulated gene was LIN28B . MMP9 mRNA expression was found enhanced in the ascites of chemoresistant ovarian cancer patients [42], and a recent meta-analysis indicated its positive association with poor prognosis in ovarian cancer [43]. FOXP1 expression was an independent risk factor associated with chemotherapy resistance and the prognosis of patients with ovarian cancer [44].…”

Cinobufacin Suppresses Cell Proliferation via miR-494 in BGC-823 Gastric Cancer Cells

“…Many studies have demonstrated that MMP-9 (Hassan et al, 2012;Zhang et al, 2012;Akdeniz et al, 2013;Asuthkar et al, 2013;Darakhshan et al, 2013;Li et al, 2013), ERK1/2 (Romano et al, 2012), KIT (Kim et al, 2011) and PTEN are considered to be the potential targeted genes of miR-494. In present study, BAG-1 is predicted as the targeted gene of miR-494 by using bioinformatics tools TargetScan, PicTar, and Miranda.…”

Ovarian cancer: involvement of the matrix metalloproteinases

“…Platelet derived growth factor D (PDGF-D) has been also shown to promote ovarian cancer invasion and this increase in invasion is caused by PDGF-D increasing the expression of MMP2 and MMP9 (Wang et al 2011b). Finally, in a meta-analysis of 30 published studies on MMP9 and its prognostic use in ovarian cancer, the expression of MMP9 was generally positively correlated with poor prognosis (Li et al 2013). …”